$AIFF rose on the NeuroSigma partnership expanding an FDA-cleared ADHD device. Its own prior gap-up sessions of 5 percent or larger closed above the open in 8 of 14 cases.
The filing widens distribution on paper, yet revenue timing stays outside the current agreement.